SNP chips still matter because they remain the technical backbone of much consumer DNA testing. They are fast, relatively inexpensive, and good at reading common variants across hundreds of thousands of positions at once.
At the same time, the limits of SNP chips are much better understood now than they were when consumer DNA kits first boomed. The technology is strong for common-marker genotyping. It is much weaker when people expect it to behave like full sequencing.
Key Statistics on SNP Chip Technology Growth
- Grand View Research valued the broader genotyping market at $17.9 billion in 2023, with projected continued growth through 2030.
- Precedence Research estimated the global SNP genotyping market at $7.52 billion in 2025, with rapid projected growth into the next decade.
- In a large UK Biobank evaluation, SNP-chip performance for very rare pathogenic variants was poor, with only 16% of heterozygous calls below a 0.001% frequency threshold confirmed by sequencing.
Those numbers capture the real state of SNP-chip technology today: commercially important, scientifically useful, and still easy to misuse if you ask it the wrong question.
Why SNP Chips Still Grow
They are cost-efficient
SNP chips can test a huge number of known markers without the cost of reading an entire genome. That still makes them attractive for:
- ancestry testing
- pharmacogenomics panels
- large population studies
- many direct-to-consumer kits
They are mature and scalable
Labs know how to run them at scale. Consumer DNA companies know how to build products around them. That operational maturity still matters.
Where SNP Chips Are Strong
SNP chips are well suited to:
- common variant detection
- ancestry estimation
- relative matching
- trait associations based on known markers
This is why consumer ancestry kits still rely on them so heavily. For those jobs, the technology is efficient and usually sufficient.
Where SNP Chips Break Down
The problem appears when buyers assume a SNP chip is equivalent to whole genome sequencing.
It is not.
Rare pathogenic variants are the clearest example. The UK Biobank evaluation is still one of the most useful reminders that SNP chips can produce false positives when they are pushed into rare-variant interpretation.
That matters for consumer health testing because a rare-variant result may sound high stakes even when the platform is not the right tool for confident detection.
SNP Chips vs. Sequencing
| Technology | Best at | Main tradeoff |
|---|---|---|
| SNP chip | Common markers at low cost | Misses most of the genome and struggles with rare variants |
| Whole genome sequencing | Broadest variant detection | More expensive and interpretation-heavy |
The market is not replacing SNP chips overnight. It is layering sequencing on top of them in the use cases where more complete data justify the cost.
What This Means for Consumer DNA Buyers
For most ancestry buyers, SNP-chip testing is still fine.
For buyers who care about:
- rare pathogenic variants
- fuller health interpretation
- maximum genomic depth
sequencing-based products are more appropriate.
Bottom Line
SNP-chip technology is still growing because it remains fast, scalable, and commercially practical. But growth does not erase its limits. The technology is strongest when used for common-marker genotyping and weakest when asked to do sequencing-grade work.
That is the real story in 2026: SNP chips are still foundational, but the market increasingly understands where they stop being the right tool.
